Journal of Clinical Oncology
Articles in this Issue
Epigenetic profiling to identify aggressiveness markers in non-Hodgkin lymphoma via a targeted methylation-based multi-cancer early detection (MCED) blood test.
7018 Background: Non-Hodgkin lymphoma (NHL) encompasses a broad spectrum of malignancies, ranging from highly indolent to...
Urban-rural disparities in the global south: The impact of urbanicity on obesity, comorbidities, and stage at diagnosis in breast cancer.
e13628 Background: Obesity is a major risk factor for breast cancer (BC). With 87.9% of Egyptian women overweight or obese...
Postoperative circulating tumor DNA for recurrence risk assessment and adjuvant therapy decision-making in resected colorectal cancer: A systematic review and meta-analysis.
e15633 Background: Circulating tumor DNA (ctDNA) has emerged as a marker of minimal residual disease after curative-intent...
Clinical outcomes of adjuvant treatment strategies in locally advanced gastroesophageal and gastric adenocarcinoma with poor pathological response to neoadjuvant FLOT: A Turkish Oncology Group (TOG) study.
e16150 Background: Perioperative FLOT is the standard of care for locally advanced gastroesophageal adenocarcinoma. Howeve...
Enhancing hematology-oncology education through a structured AI-based board review series: An ASCO Leadership Development Education Scholars initiative.
9028 Background: As an ASCO Leadership Development Education Scholars Initiative, structured board review is essential for...
Exclusive neoadjuvant chemotherapy with the FLOT regimen protocol in resectable gastric cancer: A retrospective cohort study in a Brazilian reference center.
e16118 Background: Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is currentl...
Incidence of malignancy in dermatomyositis vs polymyositis: A systematic review and meta-analysis.
e22578 Background: Dermatomyositis (DM) and Polymyositis (PM) are the two major subtypes of idiopathic inflammatory myopat...
Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.
4512 Background: Adjuvant pembrolizumab (pembro) is standard of care in renal cell carcinoma (RCC). We explored whether pa...
BL0175, a novel nano-mediated polypeptide conjugate of protein degrader, in patients (pts) with locally advanced/metastatic HR+/HER2− breast cancer (HR+, HER2- LA/mBC): Initial results from a phase 1 study.
1078 Background: BL0175 is a novel nano-conjugate (~10 nm) composed of PEG-modified poly (amino acid), enzyme-responsive p...
Factors influencing early readmission among breast, lung, and colorectal cancer patients admitted for febrile neutropenia: A Nationwide Readmissions Database (NRD) analysis.
e13105 Background: Febrile neutropenia accounts for some of the highest mortality among oncology patients. Several patient...
Trends in leukemia-related mortality with heart failure as a contributing cause among U.S. adults aged ≥55 years, 1999–2023.
e24001 Background: Advances in leukemia therapy have improved survival, but cardiotoxic exposures and aging-related comorb...
Temporal trends in lung cancer stage at diagnosis and pre-treatment staging in United States, 2004-2022.
e20118 Background: Major advances in lung cancer detection and staging have occurred over the past two decades, including...
Assessing the effects of USP10 on pancreatic ductal adenocarcinoma metastasis via deubiquitinating and stabilizing RIOK3 to induce cytoskeleton remodeling.
e16408 Background: Metastasis is a hallmark of pancreatic ductal adenocarcinoma (PDAC) and a primary driver of its lethal...
Safety and efficacy of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: A systematic review and meta-analysis.
e16024 Background: Patients with advanced esophageal squamous cell carcinoma (ESCC) continue to have poor outcomes with ch...
Immune-related adverse events in patients with mismatch repair–deficient gynecologic malignancies.
e17534 Background: Immune checkpoint inhibitors (ICIs) have shown clinical efficacy in treating tumors that harbor mismatc...
Real-world healthcare resource utilization (HCRU) following chimeric antigen receptor (CAR) T-cell therapy in US patients treated in new authorized treatment centers (ATCs) without FACT accreditation.
e19515 Background: CAR T-cell therapy offers improved outcomes in lymphoid malignancies and multiple myeloma (MM), yet acc...
Costs per avoided event (CPAE) in adjuvant CDK4/6 inhibitor therapy: A comparative analysis of subgroups from monarchE and NATALEE trials.
e12542 Background: Assessing the economic efficiency of high-cost therapies like adjuvant CDK4/6 inhibitors for HR+/HER2-...
Evaluation of GATA6 expression as a biomarker in advanced pancreatic cancer: Real-world evidence study.
e16393 Background: Pancreatic adenocarcinoma is an aggressive disease and ranks as the fourth leading cause of cancer-rela...
Automated discovery and curation of public spatial transcriptomic datasets across multiple cancer indications.
e15010 Background: Public spatial transcriptomic datasets provide critical insights into tumor architecture and the tumor...
Temporal trends, sociodemographic factors, and healthcare utilization of immune-related adverse events in hospitalized cancer patients: A national analysis, 2016-2020.
e13606 Background: Immune checkpoint inhibitors have transformed cancer treatment, but immune-related adverse events (irAE...
Adjuvant trastuzumab with or without pertuzumab after pathologic complete response to neoadjuvant HER2-targeted therapy and chemotherapy in HER2-positive breast cancer: A retrospective cohort study.
e12503 Background: Neoadjuvant dual HER2 blockade with trastuzumab (T) and pertuzumab (P) has been shown to improve rates...
An exploratory, single-center, single-arm trial of R-ISV-FOLactis in situ vaccination for advanced soft tissue sarcoma.
2592 Background: Advanced soft tissue sarcomas (STSs) have limited treatment options and exhibit low responsiveness to imm...
Validation of a treatment-based algorithm to infer biomarker status in real-world data.
e23019 Background: Real-world (RW) precision oncology studies require accurate identification of actionable biomarkers, ye...
Pilot study of HB-200 in patients with HPV16+ head and neck squamous cell carcinoma and detectable TTMV-HPVDNA after definitive therapy.
e18038 Background: Approximately 10-15% of patients with HPV16+ HNSCC develop recurrent, incurable disease after definitiv...
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
7501 Background: AL amyloidosis is a plasma cell dyscrasia (PCD) characterized by κ or λ Ig light chain amyloid fibrils th...